References
- Haanes EJ, Canaves JM. Stealing fire: a retrospective survey of biotech patent claims in the wake of Mayo v. Prometheus. Nat Biotechnol. 2012;30:758–760.
- Chen FC. Divided infringement in the limelight of the patent battle field. Trends Biotechnol. 2016;34:771–773.
- 35 USC §271(a).
- 35 USC §271(b).
- The Supreme court of the United States. Limelight Networks, Inc. v. Akamai Technologies, Inc., 134 S. Ct. 2111 (2014).
- The supreme court of the United States. Aro Mfg. Co. v. Convertible top replacement co. 365 US 336; 1961.
- The court of appeals for the federal circuit. BMC Resources, Inc. v. Paymentech, LP., 498 F. 3d 1373 (2007).
- The court of appeals for the federal circuit. Muniauction, Inc. v. Thomson, Corp., 532 F. 3d 1318 (2008).
- The court of appeals for the federal circuit mckesson technologies v. Epic Systems, Corp., No. 2010-1291 (Fed. Cir., 2011).
- The court of appeals for the federal circuit akamai Technologies, Inc. v. Limelight Networks, Inc. No. 2009-1372, WL 4760450 (Fed. Cir., Aug. 13, 2015) ( en banc).
- The court of appeals for the federal circuit. Perkinelmer, Inc. v. Intema, Ltd. No. 2011-1577 (Fed. Cir., 2012).
- The supreme court of the United States. Mayo Collaborative Services v. Prometheus Laboratories, Inc., No. 10-1150 US (2012).
- The court of appeals for the federal circuit SiRF technology, Inc. v. International Trade Commission, 601 F. 3d 1319 (2010).
- Sachs RE. Divided infringement and the doctor-patient relationship. IP theory. Bloomington, Idiana: Indiana University Maurer School of Law. Forthcoming.
- Guidelines for examination, 2015. European Patent Office.
- Sampat BN, Ziedonis AA. Patent citations and the economic value of patents. Handbook of Quantitative Science and Technology Ressearch. Dordrecht: Springer Netherlands; 2005. p. 277–298.
- Smith D. A citation-based patent evaluation framework to reveal hidden value and enable strategic business decisions. Technol Innovation Manag Rev. 2014;4:4–13.
- Allison JR, Lemley MA, Moore KA, et al. Valueable patents. Geo L J. 2004;92:435–494.
- The Lewin Group (2008) Laboratory medicine: a national status report: Centers for Disease Control and Prevention.
- Supreme Court of the United States Alice Corporation Pty. Ltd. v. CLS Bank International et al. 573 U.S.(2014).
- Eisenberg RS. Diagnostics need not apply. J Sci Technol Law. 21.2 2015. Available from: https://www.bu.edu/jostl/archives/vol-21-2-summer-2015/
- Sachs R. Innovation law and policy: preserving the future of personalized medicine. California: UC Davis Law Review. Epub ahead of print; 2016.
- United States District Court SDI. Eli lilly and company v. Teva parenteral medicines, Inc. et al. 126 F. Supp. 3d 671 (2015).
- United States District Court EDP. Cardionet, LLC. et al. v. mednet healthcare technologies, Inc. et al. 146 F. Supp. 3d. 671 (2015).
- United states district court EDNY travel sentry, Inc. v. Tropp, F.Supp.3d (2016) WL36400645.
- Love BJ, Ambwani S. Inter partes review: an early look at the numbers. Univ Chicago Law Rev. 2014;81:93–107.
- Liddicoat J, Whitton T, Nicol D. Are the gene-patent storm clouds dissipating? A global snapshot. Nat Biotechnol. 2015;33:347–352.